About Careers MedBlog Contact us

Oral Therapy Drug for Multiple Sclerosis Gets Approval

by Julia Samuel on February 17, 2015 at 11:00 AM
Font : A-A+

Oral Therapy Drug for Multiple Sclerosis Gets Approval

The national drug controller, Drug Controller General of India (DCGI), has approved a new oral therapy drug for multiple sclerosis, developed by Biogen Idec Biotech India.

The company has received approval for the first oral therapy drug for multiple sclerosis, Tecfidera by the DCGI.


Biogen Idec India Acting Managing Director Pooja Vatsyayan said, "We believe Tecfidera provides a new option for patients in India, particularly as it provides the convenience of oral dosing."

The clinical trials conducted for the approval of the drug involved two-phase III studies more than 2600 patients all around the world. Patients from India also were part of clinical research, Biogen Idec India said.

Tecfidera is the first oral drug for the treatment of relapsing-remitting multiple sclerosis (RRMS) in India, it added.

Multiple sclerosis is a disease, which affects brain and spinal cord and is the most common cause of non-traumatic neurological disability afflicting young adults, Biogen Idec India said.

Source: Medindia


Recommended Reading

Latest Drug News

 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
Sacubitril/valsartan Unleashes Hope for Heart Failure Patients
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Oral Therapy Drug for Multiple Sclerosis Gets Approval Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests